Source: Beximco Pharmaceuticals Ltd. (BXPHARMA) | FY 2016-17 | Page 45

# Notes to the Financial Statements

**Reporting Period:** For the year ended June 30, 2017  
**Reporting Currency & Multiplier:** BDT (Amount in Taka) | **Scale Multiplier:** 1.0

### 30. Finance Cost

| Particulars | July 2016- June 2017 (12 Months) | January 2015- June 2016 (18 Months) | January- June 2016 (6 Months) | January- December 2015 (12 Months) |
| --- | --- | --- | --- | --- |
| Interest on Working Capital Loan | 303,316,773 | 588,417,111 | 166,656,402 | 421,760,709 |
| Interest on Project / Consortium Loan | 13,904,256 | 152,835,514 | 35,067,043 | 117,768,471 |
| Interest on Lease Finance | 111,145,912 | 149,565,303 | 71,030,756 | 78,534,547 |
| Interest on Loan from PF, WPPF & Welfare Fund | 107,554,563 | 98,800,975 | 37,698,000 | 61,102,975 |
| Other Bank Charges | 21,081,658 | 40,563,498 | 10,759,966 | 29,803,532 |
| [Total Finance Cost] | 557,003,162 | 1,030,182,401 | 321,212,167 | 708,970,234 |

### 32. Income Tax Expenses

| Particulars | July 2016- June 2017 (12 Months) | January 2015- June 2016 (18 Months) | January- June 2016 (6 Months) | January- December 2015 (12 Months) |
| --- | --- | --- | --- | --- |
| (a) Current Tax |  |  |  |  |
| (i) Tax provision for current period (Note 3.9) | 627,764,437 | 766,053,375 | 310,173,315 | 455,880,060 |
| (ii) Short/(Excess) Provision for earlier period | (35,781,848) | (29,913,148) | - | (29,913,148) |
| [Subtotal Current Tax] | 591,982,589 | 736,140,227 | 310,173,315 | 425,966,912 |
| (b) Deferred Tax Expense / (Income) | 72,803,945 | (26,356,152) | 16,765,213 | (43,121,365) |
| [Total Income Tax Expenses] | 664,786,534 | 709,784,075 | 326,938,528 | 382,845,547 |

### 33. Other Comprehensive Income- Unrealized Gain/(Loss)

| Particulars | July 2016- June 2017 (12 Months) | January 2015- June 2016 (18 Months) | January- June 2016 (6 Months) | January- December 2015 (12 Months) |
| --- | --- | --- | --- | --- |
| Fair Value Gain/(Loss) on Investment in Listed Shares | 1,953,407 | (1,013,093) | (661,955) | (351,138) |
| Exchange Rate Fluctuation Gain on- Investment in Biocare Manufacturing | 626,100 | - | - | - |
| [Total Other Comprehensive Income- Unrealized Gain/(Loss)] | 2,579,507 | (1,013,093) | (661,955) | (351,138) |

### 34. Earnings Per Share (EPS)

| Particulars | July 2016- June 2017 (12 Months) | January 2015- June 2016 (18 Months) | January- June 2016 (6 Months) | January- December 2015 (12 Months) |
| --- | --- | --- | --- | --- |
| (a) Earnings attributable to the Ordinary- Shareholders | 2,226,695,124 | 2,948,053,854 | 993,769,338 | 1,954,284,516 |
| (b) Weighted average number of Ordinary Shares- outstanding during the year (Note 3.15) | 405,556,445 | 405,556,445 | 405,556,445 | 405,556,445 |
| Earnings Per Share (EPS) / Adjusted EPS | 5.49 | 7.27 | 2.45 | 4.82 |

### 35. Related Party Disclosures

| Name of Related Parties | Nature of Transactions | Value of Transaction | Balance at year end |
| --- | --- | --- | --- |
| (a) I & I Services Ltd. | Local Delivery Distribution Commission | 16,340,168,784 218,636,233 | 1,730,967,045 - |
| (b) Bangladesh Export Import Co. Ltd. | Short Term Investment & Interest there on | 552,460,907 | 886,576,906 |

### 36. Particulars of Disposal of Property, Plant and Equipment

| Particulars of Assets | Cost | Accumulated Depreciation | Written Down Value | Sales Price | Profit / (Loss) | Mode of Disposal | Name of Parties |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Office Equipment | 16,230,014 | 13,405,593 | 2,824,421 | 405,245 | (2,419,176) | Negotiation | Various Individuals |
| Plant & Machinery | 46,280,682 | 29,045,316 | 17,235,366 | 16,822,853 | (412,513) | Negotiation | Various Individuals |
| Furniture & Fixture | 9,694,209 | 7,615,710 | 2,078,499 | 1,973,020 | (105,479) | Negotiation | Various Individuals |
| Transport & Vehicle | 7,723,530 | 6,006,797 | 1,716,733 | 2,858,009 | 1,141,276 | Negotiation | Various Individuals |

### 37. Payment / Perquisites to Managers and Directors

| Particulars | July 2016 - June 2017 |
| --- | --- |
| Remuneration | 203,028,198 |
| Gratuity | 7,565,950 |
| Contribution to Provident Fund | 9,037,540 |
| Bonus | 22,697,850 |
| Medical | 5,935,390 |
| Others | 6,095,629 |
| Total | 254,360,557 |